• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

What to Expect from GE's Health Care Conference on Thursday

One of General Electric's biggest liabilities will be outlined on Thursday.
By KEVIN CURRAN Mar 06, 2019 | 04:57 PM EST
Stocks quotes in this article: GE, DHR

General Electric's (GE) leadership has its work cut out for it at its insurance "teach-in" on Thursday.

The conference will come to pass after a Wednesday that saw the second-largest one-day drop in GE shares of the Larry Culp era at the company.

The insurance business has been a sore spot for the Boston-based industrial giant in recent years, adding to pain across the power and industrial-based businesses that stung the shares on Wednesday.

Most notable of recent mishaps in the segment was the $6.2 billion after-tax charge disclosed in January 2018, which was followed by an announcement of a plan to set aside $15 billion over seven years to cover hundreds of thousands of years-old claims.

"At a time when we are moving forward as a company, a charge of this magnitude from a legacy insurance portfolio in run-off for more than a decade is deeply disappointing," former CEO John Flannery said at the time.

That precipitated a number of investor lawsuits and backlash against the company, which saw its stock fall precipitously.

The hangover of this business has been an albatross around the company's neck that has raised questions among analysts as to how GE will continue to come up with cash.

"We anticipate a deep-dive into the assumptions and calculations that determined that GE will need to fund another $9 billion into its insurance subsidiaries through 2024," RBC Capital Markets analyst Deane Dray said. "The key assumptions that will likely be discussed include morbidity, mortality, terminations, premium rate increases, discount rates, and more."

A timeline and a more firm actuarial estimation will be necessary to be highlighted by VP of Investor Communications Steve Winoker and senior members of the Insurance leadership team.

Considering traditionally strong businesses like GE Capital Aviation Services are still on the block by analyst estimations, and its prominent BioPharma business is being sold to Larry Culp's former company, Danaher (DHR) , the bleeding at this business needs to be clotted soon.

It will be incumbent upon the company, perhaps more so than any time in the past year, to explain how the tourniquet can be applied.

A webcast for the event can be found on GE's investor relations website. The broadcast will begin at 10 a.m. ET.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | Stocks | Bearish Bet | Biotechnology | Healthcare | Science | Analyst Actions | U.S. Equity | Stock of the Day

More from Stocks

Marveling at the Market's Move? It's All About Momentum

James "Rev Shark" DePorre
Jan 19, 2021 4:41 PM EST

No news can explain the action -- whether the bears believe it or not.

Surface Oncology Is Set for Further Gains - How to Buy It

Bruce Kamich
Jan 19, 2021 3:25 PM EST

Here's our price objective.

My Preference With OneSpan Is Calls So I Can Define My Risk

Timothy Collins
Jan 19, 2021 2:36 PM EST

The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.

A Top Biotechnology Play for 2021

James "Rev Shark" DePorre
Jan 19, 2021 2:07 PM EST

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

Boot Barn Gets a Quant Upgrade: Do the Charts Fit?

Bruce Kamich
Jan 19, 2021 1:53 PM EST

Here's our latest analysis and trading strategy for the shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login